KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Deferred Taxes (2022 - 2025)

Historic Deferred Taxes for Neogenomics (NEO) over the last 4 years, with Q4 2025 value amounting to $2.7 million.

  • Neogenomics' Deferred Taxes rose 7313.62% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.4 million, marking a year-over-year increase of 941.37%. This contributed to the annual value of $3.4 million for FY2025, which is 941.37% up from last year.
  • As of Q4 2025, Neogenomics' Deferred Taxes stood at $2.7 million, which was up 7313.62% from -$869000.0 recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Deferred Taxes peaked at $5.7 million during Q2 2022, and registered a low of -$869000.0 during Q3 2025.
  • Its 4-year average for Deferred Taxes is $2.1 million, with a median of $2.3 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' Deferred Taxes was 10905.26% (2025), while the steepest drop was 45614.75% (2025).
  • Neogenomics' Deferred Taxes (Quarter) stood at $3.3 million in 2022, then crashed by 45.34% to $1.8 million in 2023, then decreased by 14.18% to $1.6 million in 2024, then surged by 73.14% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q4 2025, -$869000.0 for Q3 2025, and $993000.0 during Q2 2025.